Previous 10 | Next 10 |
2024-04-03 13:47:44 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics settles all...
2024-04-01 17:30:31 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics divests PIC...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief...
2024-02-16 16:30:40 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics reports mix...
Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and Syntrax products AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focuse...
2024-01-23 10:16:28 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics reports mix...
225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient Recovery AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body...
2024-01-14 14:04:11 ET Summary AngioDynamics' latest quarter earnings missed expectations. The company is facing weaker-than-anticipated sales following the rollout of new products forcing management to revise lower full-year guidance. We expect shares to remain volatile until...
News, Short Squeeze, Breakout and More Instantly...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...
AZZ Inc. (AZZ) is expected to report $1.31 for Q1 2025 Express Inc. (EXPRQ) is expected to report for Q1 2025 Aeon Co. Ltd. ADR (AONNY) is expected to report for Q1 2025 Altamira Therapeutics Ltd. (CYTO) is expected to report for Q1 2024 Bassett Furniture Industries Incorporated (...